JNJ's $14B acquisition of ITCI bolsters its portfolio with Caplyta, showing strong sales and patent protection until 2033.

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression ...

The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, with no statistically significant difference observed between the treatment ...

Net product sales of CAPLYTA were $680.5 million for the full year 2024. This represents an increase of 47% compared to 2023.

Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator.

Intra-Cellular reports mixed fourth-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven ...

Escalating concerns over impending tariffs and President Trump's foreign policies have fueled uncertainty and instability in ...

In a remarkable display of market confidence, Intra-Cellular Therapies Inc. (NASDAQ:ITCI) stock has reached an all-time high, touching a price level of $128.01. According to InvestingPro data, the ...

In a recent special meeting, Firefly Neuroscience, Inc. (NASDAQ:AIFF), a Delaware-based prepackaged software company with a market capitalization of $122.84 million, received stockholder approval for ...